Interestingly, a clinical trial evaluating the effects of a selective orally active inhibitor of the P2X7 receptor (AZD9056) showed beneficial effects in patients with moderate-to-severe Crohn's Disease (Eser et al., 2015). The gene discussed is P2RX7; the disease is Crohn disease.